Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer

Nanoform Finland

[phone]

Investors
Plc
Henri von Haartman, Director of Investor Relations
[e-mail]
[phone]

Media
Orientation Marketing
Chris Halling, Director of Communications
[e-mail]
[phone]

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (HEL: NANOFH) and Stockholm (STO: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, [phone]. For more information, please visit www.nanoform.com.

About PlusVitech

PlusVitech is a Spanish biotechnology/pharmaceutical/medicine company, spin-off of the Andalusian Health Service. It was founded in 2013 in Seville as a result of the multidisciplinary work of an enthusiastic and qualified team, with the aim of improving the treatment of high impact diseases such as cancer, and has a subsidiary company in Boston (USA). PlusVitech's most powerful solution (called PVT-1) is a repositioning of drugs for which it has clinical evidence in patients who have experienced complete remission in different types of cancer. PlusVitech has a wide portfolio of different international patents that protect for Cancer, the use of this and other synergistic drugs, as well as other innovations, such as a companion diagnostic test that optimizes these treatments for each patient. For more information, please visit www.plusvitech.com/en

Forward-Looking Statements 

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2023 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-and-plusvitech-partner-to-repurpose-aprepitant-as-a-treatment-for-lung-cancer,c3958300

The following files are available for download:

https://mb.cision.com/Main/18905/3958300/2718352.pdf

Release

 

View original content:https://www.prnewswire.co.uk/news-releases/nanoform-and-plusvitech-partner-to-repurpose-aprepitant-as-a-treatment-for-lung-cancer-302111314.html